UK-based Rosemont Pharmaceuticals has appointed a new chair with a wealth of experience in the US pharma market.

A large-scale real-world study in the USA has reinforced the effectiveness of Beyfortus (nirsevimab-alip), the respiratory syncytial virus (RSV) preventive developed by French drugmaker Sanofi and ...

UK government-backed Cell and Gene Therapy Catapult (CGT Catapult), a tech and innovation organization specializing in the ...

US healthcare giant Johnson & Johnson has announced that the European Commission (EC) has approved a new indication and an indication extension for Darzalex (daratumumab) and Imbruvica (ibrutinib), ...

Russian nano giant Rusnano is cutting its pharmaceutical business by beginning a search for buyers for its major ...

Privately-held Spanish CNS specialist Minoryx Therapeutics and Germany’s Neuraxpharm Group today announce that the marketing authorization application (MAA) for Minoryx’ lead candidate Nezglyal ...

Dispatch Bio has announced its official launch, with the stated ambition of engineering a universal treatment across solid tumors, which represent approximately 90% of cancers worldwide.

Switzerland-based Pharvaris yesterday announced the pricing of an underwritten offering of: 8,250,000 of its ordinary shares at a price of $20.00 per share and to one investor, pre-funded warrants to ...

Once dominated by Western markets, China and India are now emerging as leaders in small molecule development. Indeed, they ...

The European Commission has approved Swiss pharma giant Roche’s Itovebi (inavolisib), in combination with palbociclib ...

Scancell Holdings, the developer of Immunobody and Moditope active immunotherapies to treat cancer, has announced further positive data from the ongoing Phase II SCOPE trial of SCIB1/iSCIB1+ ...

Shares of French clinical-stage biotech Abivax were up an astonishing 389% at 43.55 euros in early trading, after, late yesterday, it announced positive top-line results from its Phase III ABTECT-1 ...